Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI-Based Lung Cancer Screening Device on February 09, 2026 CADe/CADx Cholestasis-edema syndrome, Norwegian type Detection eyonis Malignant neoplasm of lung Median Technologies Screening for cancer United States Food and Drug Administration +